Intra-Cellular Therapies Inc $ 7.76 -0.18 (-2.21%)
Volume:
607,197
Avg Vol (1m):
905,240
Market Cap $:
427.87 Mil
Enterprise Value $:
165.40 Mil
P/E (TTM):
0.00
P/B:
1.67
Manual of Stocks™ Web
Financial Strength | 5.4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 12.5 | ||
| Debt-to-Equity | 0.09 | ||
| Debt-to-EBITDA | -0.15 | ||
| Piotroski F-Score | 1 | ||
| Beneish M-Score | -5.06 | ||
| WACC vs ROIC | |||
Profitability | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| ROE % | -48.08 | ||
| ROA % | -42.75 | ||
| ROC (Joel Greenblatt) % | -1690.56 | ||
| 3-Year Revenue Growth Rate | -100 | ||
| 3-Year EBITDA Growth Rate | 0.8 | ||
| 3-Year EPS without NRI Growth Rate | 0.8 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.67 | ||
| EV-to-EBIT | -1.07 | ||
| EV-to-EBITDA | -1.07 | ||
| Current Ratio | 8.86 | ||
| Quick Ratio | 8.86 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.67 | ||
| Earnings Yield (Greenblatt) % | -93.46 |